Novel Composite Clinical Endpoints and Risk Scores Used in Clinical Trials in Pulmonary Arterial Hypertension

This review is from the PVRI Innovative drug Development Initiative which includes academic, regulatory and pharmaceutical leaders in the field of PAH. They address changes in the traditional endpoints in the trials for PAH and offer newer approaches including the use of risk scores to enrich the patient pool appropriate for the type of treatment used.

Source: https://pubmed.ncbi.nlm.nih.gov/33282190/